Medtronic plc. (MDT) Stock Price & How to Invest

Medtronic is one of the largest medical device companies in the world, designing, manufacturing, and selling therapies and devices across a broad range of chronic and acute conditions. Its business spans three main areas after October 2026: Cardiovascular (pacemakers, defibrillators, heart valves, and cardiac ablation), Neuroscience (spine implants, neuromodulation for pain and movement disorders, and surgical navigation), and Medical Surgical (surgical stapling, energy devices, and a growing robotic-surgery platform). Its former Diabetes unit (insulin pumps and continuous glucose monitoring) was carved out as MiniMed, which listed on Nasdaq under MMED; on October 15, 2026 Medtronic exchanged its remaining 252.8 million MiniMed shares for Medtronic shares in an exchange offer that was 5.4 times subscribed, so it no longer owns any of MiniMed. The company sells primarily to hospitals, surgeons, and health systems, generating durable, recurring demand tied to procedure volumes and chronic-disease management. Medtronic's scale gives it deep relationships with providers, a large installed base of devices, and the resources to fund extensive R&D and acquisitions. Growth depends on new product cycles, pipeline approvals, and global expansion, especially in emerging markets. Founded in 1949 and headquartered in Ireland for tax purposes (operationally rooted in Minnesota), Medtronic is a large-cap, dividend-growing medical-technology company tied to long-term healthcare demand and aging demographics, with trailing revenue of about $37.5 billion as of October 2026.

Medtronic has at times delivered sluggish organic growth, raising concerns that its scale slows innovation relative to nimbler competitors like Boston Scientific and Edwards Lifesciences. The Hugo robotic platform faces an entrenched Intuitive Surgical. The MiniMed separation removes diabetes but adds near-term noise: reported results, guidance and comparisons will shift as the unit leaves the numbers, and analysts expect EPS of about $1.33 for the quarter ending October 2026, slightly below the year-earlier level. Device companies face reimbursement pressure, hospital budget constraints, FDA approval and recall risk, and litigation exposure. A large international footprint brings currency headwinds, and debt stood near $28 billion against about $8.8 billion of cash as of October 2026. The stock is roughly flat over the past year despite faster sales growth. New-product execution, pipeline timing, and the ability to sustain organic growth remain the key swing factors for the investment case.

25 analysts publish price targets on MDT, averaging $104.40 against a $94.75 price as of October 2026, or +10.2%. The published targets run from $85.00 to $121.00, a moderate spread, and the ratings split 19 buy, 10 hold, 0 sell. Over the last six months there have been 7 raises and 1 cut among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full MDT forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on Medtronic plc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Diversified device portfolio. Medtronic spans cardiovascular, neuroscience, and medical surgical, so no single product or therapy dominates results. The most optimistic published target, $121.00, assumes this works close to its best case.

The case against. Medtronic has at times delivered sluggish organic growth, raising concerns that its scale slows innovation relative to nimbler competitors like Boston Scientific and Edwards Lifesciences. The most pessimistic target, $85.00, is roughly what MDT is worth if this bites instead.

Read the full bull and bear case on MDT, including what would have to change to break either one. Walnut is not an investment adviser.

No. Medtronic plc. (MDT) has not split its stock in the last 10 years. That is a statement about the window we check rather than about the company’s entire history, so an older split is possible. It also matters less than it once did: fractional shares mean a high price per share no longer keeps smaller investors out, which removed most of the practical reason to split.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Medtronic plc.'s investor relations page or your broker.

• Revenue (TTM): ~$37.5 billion, up ~14% year over year in the July 2026 quarter
• Margins: ~65% gross, ~19% operating, ~14% net
• Net income (TTM): ~$5.2 billion
• EPS: ~$4.07 GAAP trailing; ~$6.41 forward estimate
• P/E: ~23x trailing GAAP, ~15x forward
• Dividend yield: ~3.0% ($2.88 a year), a Dividend Aristocrat
• Free cash flow (TTM): ~$5.4 billion
• Market cap: ~$121 billion

At about $95 on October 16, 2026, Medtronic trades near 15 times forward earnings, a moderate multiple next to faster-growing medtech peers, while the GAAP trailing P/E of about 23x includes acquisition amortization. The 25 analysts tracked by Yahoo Finance hold a mean target near $104. The next report, expected around November 17, 2026, will be the first read on the company after the MiniMed exit, with consensus at about $1.33 of EPS on $9.5 billion of revenue.

If you want MDT exposure as part of a larger bundle rather than directly, these ETFs hold it meaningfully. Weights are approximate and refresh quarterly.

These are the investment theses MDT naturally fits into. Each links to a full theme guide listing every other stock that belongs and the ETFs commonly used as a passive proxy.

Other names that sit close to MDT: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get MDT exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it (NOBL, SDY, SPYD), which spreads the position across many companies. Or build it into a focused thematic portfolio, so MDT sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where MDT fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

Medtronic (MDT) is a broad medtech Dividend Aristocrat whose diversified device base and aging-population tailwind produce reliable cash flow and a yield of roughly 3% (as of October 2026), offset by a history of slow organic growth versus nimbler peers like Boston Scientific and Edwards. Sales growth picked up in its latest quarter, and the MiniMed separation leaves a slimmer company focused on cardiovascular, neuroscience and surgery. In a portfolio it behaves as a defensive healthcare and dividend-growth holding whose total return hinges on reaccelerating new product cycles, not on the economic cycle.

Whether MDT is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is MDT a buy or a sell?, and where the stock could go from here in the MDT stock forecast.

For income investors, whether MDT pays a dividend and how the payout looks is covered in does MDT pay a dividend? And to weigh MDT against a peer, read the full side-by-side comparisons: MDT vs ABT and MDT vs JNJ.